Back to results

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia (ETERNAL)

Primary Purpose

Obesity, Dyslipidemias

Status

Terminated

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

rimonabant

Placebo

About this trial

This is an interventional treatment trial for Obesity

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

BMI > 27 kg/m² and < 40 kg/m²,
Waist Circumference > 88 cm in women; > 102 cm in men,
HDL cholesterol < 40 mg/dL (1.03 mmol/L) for men; < 50 mg/dL (1.29 mmol/L) for women, and/or Triglycerides ≥ 150 mg/dL (1.69 mmol/L),
LDL cholesterol up to 155 mg/dl (4.00 mmol/L) including patients on a stable dose of statins and/or Ezetimibe therapy for at least 8 weeks prior to screening

Concomitant medications:

Current treatment with statins and/or ezetimibe and/or antihypertensive therapy must be at fixed and stable dose for at least 8 weeks prior to screening visit,
Patients, who are willing and in the opinion of the Investigator safely assumed to remain on stable and fixed doses of antihypertensive, and/or statins and/or ezetimibe without adding additional medications or changing current treatment for the duration of the trial.

Exclusion Criteria:

Pregnant or breast-feeding women, or women planning to become pregnant or breastfeed (excluded by pregnancy test),
Absence of medically approved contraceptive methods for female of childbearing potential,
History of very low-calorie diet within 3 months prior to screening visit (lower than 1200 Kcal/day),
Weight change > 5 kg within 3 months prior to screening visit,
History of surgical procedures for weight loss (e.g., stomach stapling, bypass),
History of bulimia or anorexia nervosa as per DSM-IV criteria
Presence of any clinically significant endocrine disease according to the investigator, in particular known abnormal TSH and free T4 blood level (Patients treated with thyroid replacement therapy must be on fixed and stable dose for at least 3 months prior to screening and must be in euthyroïd status),
Established type 1 or 2 diabetes treated, or with at least 2 measures of fasting blood glucose ≥ 126 mg/dl,
Triglyceride level > 400 mg/dL (4.52 mmol/L),
Systolic blood pressure > 160 mm Hg or diastolic blood pressure >100 mmHg at screening visit,
Known severe renal dysfunction (creatinine clearance < 30 ml/min) or nephrotic syndrome or urinalysis (performed at screening by dipstick) showing 2+ or more protein,
Known severe hepatic impairment or AST and/or ALT > 3 times the upper limit of normal at screening,
Presence of any condition (medical, including clinically significant abnormal laboratory tests, psychological, social or geographical) actual or anticipated that the investigator feels would compromise the patient's safety or limit his/her successful participation to the study. In particular :
- Cardiac abnormalities: cardiac failure status NYHA III or IV, relevant acute abnormal finding seen on ECG at screening or within 6 months before screening,
- Any current malignancy or any cancer within the past five years (except adequately treated basal cell skin cancer or cervix carcinoma in situ),
- Significant haematology abnormalities (haemoglobin < 100 g/L and/or neutrophils < 1.5 G/L and/or platelets < 100 G/L),
- Acute psychiatric disorders, or mental condition which could interfere with the patient's compliance or safe participation in the study,
- Patient treated for epilepsy
Ongoing major depressive illness,
Uncontrolled psychiatric illness,
History of alcohol or other substance abuse,
Hypersensitivity /intolerance to the active substance or to any of the excipients such as lactose,

Concomitant medications prior to study entry::

Administration of any investigational treatment (drug or device) within 30 days prior to screening,
Previous participation in a Rimonabant study or previous administration of Rimonabant,
Administration of any of the following within 3 months prior to screening visit:
- anti obesity drugs (eg, sibutramine, orlistat),
- other drugs for weight reduction (phentermine, amphetamines),
- herbal preparations for weight reduction,
- nicotinic acid, fibrates or bile acid sequestrants,
- Prolonged use (more than one week) of systemic corticosteroids, neuroleptics,
- Omega-3 fatty acid approved medication
Ongoing antidepressive treatment (including bupropion)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Arm Description

Outcomes

Primary Outcome Measures

Change in HDL-C and triglyceride levels

Secondary Outcome Measures

Waist circumference and body weight

Glycemic parameters : FPG, fasting insulinemia, HbA1c,

Lipid parameters : Total Cholesterol, HDL-C, LDL-C, triglyceride levels

Inflammatory parameter : Hs-CRP

Quality of life : IWQOL questionnaire completed

Incidence of adverse events in each group, including neuro-psychiatric adverse events

Standard laboratory assessments

In selected sites, a sub study will be conducted in which additional Lipid parameters will be measured: HDL subfractions, Apo A1, Apo A2, Apo B and Apo C3, Lp A1, LpA1/A2, Lp(a), Oxidized-LDL and LDL size

In selected sites, a sub study will be conducted in which additional Inflammatory parameters will be measured: Adiponectin-High Molecular Weight, Intracellular adhesion molecule 1(ICAM-I) and TNFalpha.

Full Information

NCT ID

NCT00412698

First Posted

December 15, 2006

Last Updated

December 9, 2010

Sponsor

Sanofi

1. Study Identification

Unique Protocol Identification Number

NCT00412698

Brief Title

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia

Acronym

ETERNAL

Official Title

A European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Dyslipidemia With or Without Other Comorbidities

Study Type

Interventional

2. Study Status

Record Verification Date

December 2010

Overall Recruitment Status

Terminated

Why Stopped

Company decision has been taken in light of recent demands by certain national health authorities

Study Start Date

December 2006 (undefined)

Primary Completion Date

January 2009 (Actual)

Study Completion Date

January 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor

Sanofi

4. Oversight

5. Study Description

Brief Summary

Primary : To determine the effect of Rimonabant 20 mg on changes in, HDL-Cholesterol (HDL-C), triglyceride levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with dyslipidemia with or without other associated comorbidities. Main Secondary : To determine the effect of 12 months Rimonabant treatment versus placebo on changes in waist circumference (WC), body weight, glycemic and lipid parameters. To assess the safety of 12 months Rimonabant treatment versus placebo in these patients. In selected sites, a sub study will be conducted to determine the effect of 12 months of Rimonabant on additional lipoprotein and inflammatory parameters.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Obesity, Dyslipidemias

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigator

Allocation

Randomized

Enrollment

645 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Arm Type

Experimental

Arm Title

Arm Type

Placebo Comparator

Intervention Type

Drug

Intervention Name(s)

rimonabant

Intervention Description

Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning. White film-coated tablets, for oral administration containing 20 mg of active rimonabant

Intervention Type

Drug

Intervention Name(s)

Placebo

Intervention Description

Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.

Primary Outcome Measure Information:

Title

Change in HDL-C and triglyceride levels

Time Frame

From baseline to end of treatment

Secondary Outcome Measure Information:

Title

Waist circumference and body weight

Time Frame

At each visit

Title

Glycemic parameters : FPG, fasting insulinemia, HbA1c,

Time Frame

Prior to baseline, month 3, month 6 and month 12.

Title

Lipid parameters : Total Cholesterol, HDL-C, LDL-C, triglyceride levels

Time Frame

Prior to baseline, month 3, month 6 and month 12.

Title

Inflammatory parameter : Hs-CRP

Time Frame

Prior to baseline, month 3, month 6 and month 12.

Title

Quality of life : IWQOL questionnaire completed

Time Frame

At baseline, month 3, month 6, month 9 and month 12.

Title

Incidence of adverse events in each group, including neuro-psychiatric adverse events

Time Frame

Prior to baseline, month 3, month 6 and month 12.

Title

Standard laboratory assessments

Time Frame

Prior to baseline and month 12

Title

Time Frame

Prior to baseline and at month 12

Title

Time Frame

Prior to baseline and at month 12

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

75 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: BMI > 27 kg/m² and < 40 kg/m², Waist Circumference > 88 cm in women; > 102 cm in men, HDL cholesterol < 40 mg/dL (1.03 mmol/L) for men; < 50 mg/dL (1.29 mmol/L) for women, and/or Triglycerides ≥ 150 mg/dL (1.69 mmol/L), LDL cholesterol up to 155 mg/dl (4.00 mmol/L) including patients on a stable dose of statins and/or Ezetimibe therapy for at least 8 weeks prior to screening Concomitant medications: Current treatment with statins and/or ezetimibe and/or antihypertensive therapy must be at fixed and stable dose for at least 8 weeks prior to screening visit, Patients, who are willing and in the opinion of the Investigator safely assumed to remain on stable and fixed doses of antihypertensive, and/or statins and/or ezetimibe without adding additional medications or changing current treatment for the duration of the trial. Exclusion Criteria: Pregnant or breast-feeding women, or women planning to become pregnant or breastfeed (excluded by pregnancy test), Absence of medically approved contraceptive methods for female of childbearing potential, History of very low-calorie diet within 3 months prior to screening visit (lower than 1200 Kcal/day), Weight change > 5 kg within 3 months prior to screening visit, History of surgical procedures for weight loss (e.g., stomach stapling, bypass), History of bulimia or anorexia nervosa as per DSM-IV criteria Presence of any clinically significant endocrine disease according to the investigator, in particular known abnormal TSH and free T4 blood level (Patients treated with thyroid replacement therapy must be on fixed and stable dose for at least 3 months prior to screening and must be in euthyroïd status), Established type 1 or 2 diabetes treated, or with at least 2 measures of fasting blood glucose ≥ 126 mg/dl, Triglyceride level > 400 mg/dL (4.52 mmol/L), Systolic blood pressure > 160 mm Hg or diastolic blood pressure >100 mmHg at screening visit, Known severe renal dysfunction (creatinine clearance < 30 ml/min) or nephrotic syndrome or urinalysis (performed at screening by dipstick) showing 2+ or more protein, Known severe hepatic impairment or AST and/or ALT > 3 times the upper limit of normal at screening, Presence of any condition (medical, including clinically significant abnormal laboratory tests, psychological, social or geographical) actual or anticipated that the investigator feels would compromise the patient's safety or limit his/her successful participation to the study. In particular : Cardiac abnormalities: cardiac failure status NYHA III or IV, relevant acute abnormal finding seen on ECG at screening or within 6 months before screening, Any current malignancy or any cancer within the past five years (except adequately treated basal cell skin cancer or cervix carcinoma in situ), Significant haematology abnormalities (haemoglobin < 100 g/L and/or neutrophils < 1.5 G/L and/or platelets < 100 G/L), Acute psychiatric disorders, or mental condition which could interfere with the patient's compliance or safe participation in the study, Patient treated for epilepsy Ongoing major depressive illness, Uncontrolled psychiatric illness, History of alcohol or other substance abuse, Hypersensitivity /intolerance to the active substance or to any of the excipients such as lactose, Concomitant medications prior to study entry:: Administration of any investigational treatment (drug or device) within 30 days prior to screening, Previous participation in a Rimonabant study or previous administration of Rimonabant, Administration of any of the following within 3 months prior to screening visit: anti obesity drugs (eg, sibutramine, orlistat), other drugs for weight reduction (phentermine, amphetamines), herbal preparations for weight reduction, nicotinic acid, fibrates or bile acid sequestrants, Prolonged use (more than one week) of systemic corticosteroids, neuroleptics, Omega-3 fatty acid approved medication Ongoing antidepressive treatment (including bupropion) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Valérie Pilorget, MD

Organizational Affiliation

Sanofi

Official's Role

Study Director

Facility Information:

Facility Name